Ozempic Gastroparesis Settlement: Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Legal Guidance

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This legacy heritage has empowered individuals to make informed decisions about their well-being, often by translating complex biomedical concepts into accessible knowledge. Within this broad context, discussions around metabolic health and pharmaceutical interventions have become increasingly prominent, reflecting evolving scientific understanding and patient experiences. As public awareness has grown, so too has attention to specific therapeutic agents and their potential unintended consequences. One such area of focus involves glucagon-like peptide-1 receptor agonists, commonly prescribed for type 2 diabetes and weight management. Among these, Ozempic has garnered significant attention not only for its efficacy but also for reports linking its use to gastrointestinal complications, including gastroparesis—a condition characterized by delayed gastric emptying. This shift from general health education to a more targeted concern about drug exposure and associated risks represents a natural progression in the information landscape. The transition from broad health literacy to specific exposure-related questions is now crystallizing around legal and medical inquiries. Individuals who have used Ozempic and subsequently developed gastroparesis are seeking clarity on settlement criteria, marking a pivot from general awareness to actionable, case-specific information. This evolution underscores the dynamic nature of health communication, where foundational knowledge serves as a springboard for addressing emerging, real-world concerns.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, its use has been associated with gastrointestinal adverse reactions, including conditions that may be linked to gastroparesis, a disorder characterized by delayed gastric emptying without mechanical obstruction. Clinical presentation of gastroparesis typically includes nausea, vomiting, early satiety, bloating, and abdominal pain. Diagnosis often involves gastric emptying scintigraphy or breath testing. In the context of Ozempic, the drug's pharmacology as a GLP-1 receptor agonist slows gastric emptying, which is a known mechanism of action. This effect can exacerbate or unmask gastroparesis in susceptible individuals. The label for Ozempic reports that in placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% associated with Ozempic include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these data, the symptoms overlap significantly, and the drug's effect on gastric motility provides a mechanistic pathway.

Mechanism of Action and Risk Factors

GLP-1 receptor agonists like semaglutide delay gastric emptying by inhibiting vagal nerve activity and reducing antral contractions, which can lead to prolonged gastric retention. This mechanism is well-documented and can contribute to the development or worsening of gastroparesis, particularly in patients with pre-existing autonomic neuropathy or other risk factors. Regarding risk considerations, the adequacy of warnings for Ozempic and gastroparesis is a key issue. The label does not specifically mention gastroparesis as an adverse reaction, but it does highlight gastrointestinal adverse reactions and the potential for delayed gastric emptying. Patients who experience persistent nausea, vomiting, or abdominal pain after starting Ozempic may be at risk for gastroparesis, and the label advises discontinuation if severe gastrointestinal reactions occur. However, the lack of explicit warning about gastroparesis could be a factor in settlement considerations for affected patients. Settlement criteria often involve demonstrating that the drug caused or contributed to the condition, that the manufacturer failed to provide adequate warnings, and that the patient suffered harm as a result. The timeline between exposure and documented harm is also critical; gastroparesis symptoms typically emerge during dose escalation or after prolonged use, as seen in clinical trial data where gastrointestinal reactions were most common during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Settlement Criteria and Legal Considerations

For patients considering legal action, evidence of a causal link between Ozempic and gastroparesis may rely on the drug's known pharmacological effects, clinical trial data showing high rates of gastrointestinal adverse reactions, and individual case reports. Settlement-related considerations include the severity of the gastroparesis, the duration of symptoms, and whether the patient required medical intervention such as hospitalization or surgery. The FDA label data provide a foundation for arguing that the manufacturer was aware of the risk of significant gastrointestinal adverse reactions but did not specifically warn about gastroparesis. This gap in warning could be central to settlement negotiations. In summary, Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis, due to its mechanism of delaying gastric emptying. The label data from clinical trials show dose-dependent increases in nausea, vomiting, and other gastrointestinal issues, with higher rates at higher doses. Patients who develop gastroparesis after using Ozempic may have grounds for settlement claims based on inadequate warnings and the drug's known effects. The timeline of symptom onset during dose escalation is a key factor in establishing harm. Affected individuals should consult medical and legal professionals to evaluate their specific cases.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism of action. This can exacerbate or unmask gastroparesis, a condition of delayed gastric emptying. Clinical trial data show high rates of gastrointestinal adverse reactions, including nausea and vomiting, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the settlement criteria for Ozempic-related gastroparesis?

Settlement criteria typically require evidence that Ozempic caused or contributed to gastroparesis, that the manufacturer failed to provide adequate warnings about this risk, and that the patient suffered harm. Key factors include documented Ozempic exposure, a confirmed gastroparesis diagnosis, symptom onset during dose escalation, and severity of the condition requiring medical intervention.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.